Aesyra SA, a Lausanne, Switzerland-based developing a medical device able to accurately monitor and relieve sleep bruxism (nocturne teeth grinding), closed a first financing round of undisclosed amount.
VitaTech made the investment. Funded by the Zambon Family and by other European ultra-high-net-worth private investors and family offices, VitaTech invests in European early stage and growth-phase high-tech companies positioned at the convergence of healthcare and technology.
In conjunction with the funding, VitaTech Director Dr. Paolo Orsatti joined the board.
The company, which has already secured the IP, developed prototypes and obtained clinical data, intends to use the funds to develop AesyBiteā¢, a novel dental product that monitors and actively reduces bruxism, to pursue the industrialization, the clinical validation and the commercialization of the technology.
Led by Marco Letizia (CEO), Aesyra is a MedTech company developing next generation solutions for the monitoring and treatment of sleep diseases. The technology developed by the company has several applications in dentistry and sleep medicine at various stages of development, all of which offer significant partnering opportunities. The company works in close collaboration with medical experts from the Clinique Universitaire de MĆ©decine Dentaire de GenĆØve (CUMD) and the top-ranked opinion leaders in bruxism, dental implantology and sleep medicine.
Aesyra is a spin-off of the Laboratory of Life Sciences Electronics (Prof. Carlotta Guiducci) at the Ecole Polytechnique FƩdƩrale de Lausanne (EPFL).
FinSMEs
25/06/2019